Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral InfectionsImmunology Published on 2021-05-192022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, [키워드] addition Against clinical trial consequence coronavirus COVID-19 emerging respiratory viral infection Evidence IFN-I IFN-β Increasing individual interferon beta Intervention intranasal limit MERS nasopharyngeal observation occur post-pandemic Prophylactic Prophylaxis respiratory respiratory viral infection respiratory viral infections SARS-CoV-2 Spread supported suppressed type 1 interferon type-I interferon Vaccine variants viral respiratory infection virus [DOI] 10.3389/fimmu.2021.660298 PMC 바로가기 [Article Type] Immunology
An Intramuscular DNA Vaccine for SARS-CoV-2 Decreases Viral Lung Load but Not Lung Pathology in Syrian HamstersArticle Published on 2021-05-122022-10-29 Journal: Microorganisms [Category] COVID-19, [키워드] 2019 novel coronavirus administration Antibody Response Antibody titer Combination controls decrease DNA DNA vaccine effective interventions Efficacy evaluated Frame full length hamster host cell in vivo induce Infectious virus intramuscular intranasal load lung Lung pathology ORF pathology Prevent protective immune response public health receiving reducing reported Safe SARS-CoV-2 Spike protein syrian hamster model tested the SARS-CoV-2 vaccination Vaccine vaccine candidate Vaccines Viral load viral loads virus titer [DOI] 10.3390/microorganisms9051040 PMC 바로가기 [Article Type] Article
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferretsArticle Published on 2021-05-102022-10-30 Journal: NPJ Vaccines [Category] COVID-19, [키워드] administration adverse event AZD1222 candidate ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 against chimpanzee adenovirus-vectored vaccine Combination COVID-19 Critical effective Efficacy evaluated ferret group human clinical trials IMPROVE indicate Infection intramuscular intranasal intranasal route management oral swab pandemic phase reduce reductions in Safe SARS-CoV-2 significantly trials Vaccine vaccine candidate Vaccines viral infection Viral load [DOI] 10.1038/s41541-021-00315-6 PMC 바로가기 [Article Type] Article
Vaping Exacerbates Coronavirus-Related Pulmonary Infection in a Murine ModelPhysiology Published on 2021-05-102022-10-31 Journal: Frontiers in Physiology [Category] COVID-19, [키워드] beta coronavirus Contact Control coronavirus coronavirus disease Coronavirus infection COVID-19 cytokine Cytokines death described develop disease disease severity dysregulation E-cigarette Evidence exacerbate Fever global pandemic Histopathology indicate Infectious disease Inflammation intranasal less lung means measure MHV-A59 mice Mild Model Mortality outbreak pathology pulmonary pulmonary disease pulmonary inflammation Respiratory disease respiratory droplet risk factor SARS-CoV-2 Severe respiratory distress severity smoking spirometry suffered syndrome the SARS-CoV-2 therapeutic intervention Toxicity transmitted while WHO World Health Organization [DOI] 10.3389/fphys.2021.634839 PMC 바로가기 [Article Type] Physiology
Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease인간 회복기 혈장은 심각한 호흡기 질환으로부터 K18-hACE2 마우스를 보호합니다Animal Published on 2021-05-072022-09-12 Journal: The Journal of General Virology [Category] SARS, 진단, [키워드] angiotensin animal model animal models anti-SARS-CoV-2 antibody antibody protection Brain Brain infection brains candidate drug candidate drugs causative agent convalescent plasma COVID-19 determine develop disease Efficacy element expressing hACE2 health emergency Host Human human Angiotensin-converting enzyme human infection human infections hypersensitivity infect Infection intranasal K18 K18-hACE2 K18-hACE2 mice K18-hACE2 mouse model Keratin lesion lesions lung Lungs medical countermeasure mice mitigate Neutralizing antibodies persistence Post-infection Prevent promoter PROTECT Protective pulmonary damage receptor reduced reported Respiratory disease SARS-CoV-2 severe disease severe respiratory disease Spread subsequent Support survived Therapeutics this system transgenic mice treated Viral antigen virus [DOI] 10.1099/jgv.0.001599 PMC 바로가기 [Article Type] Animal
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19Research article Published on 2021-05-012022-10-05 Journal: The Lancet Regional Health - Europe [Category] 치료법, 치료제, [키워드] administration adverse event AEs airway allergy analyses anti-SARS-CoV-2 Antiviral Antiviral treatment assigned Asymptomatic clinically Cohort cohorts conducted coronavirus disease 19 COVID-19 criteria defined Denmark Diseases dose double-blind evaluated event Evidence exhibited expiratory finding FIVE Frequency funding healthy volunteer healthy volunteers Infection Inhaled intranasal Lung function niclosamide nitric oxide Patient Phase 1 phase 1 trial Placebo placebo group placebo-controlled predicted primary endpoint Pulmonary function test Randomized Randomly receiving reported resolved Safety serious AE single dose therapy Treatment Trial trials upper respiratory tract variable viral respiratory Volume Volunteer was determined [DOI] 10.1016/j.lanepe.2021.100084 [Article Type] Research article
Insulin fast-dissolving film for intranasal delivery via olfactory region, a promising approach for the treatment of anosmia in COVID-19 patients: Design, in-vitro characterization and clinical evaluationResearch article Published on 2021-05-012022-10-05 Journal: International journal of pharmaceutics [Category] SARS, 치료법, [키워드] alcohol Anosmia approach Characteristics clinical clinical evaluation clinical study conducted COVID-19 COVID-19 infection disintegration Fast-dissolving film Fourier transform In-vitro insulin Interaction intervention group intranasal investigated methyl cellulose olfactory Patient patients physical placebo group polymers selected significant difference significant differences significant increase the placebo group Treatment Variation were used [DOI] 10.1016/j.ijpharm.2021.120600 [Article Type] Research article
A novel pseudovirus‐based mouse model of SARS-CoV-2 infection to test COVID-19 interventionsCOVID-19 개입을 테스트하기 위한 SARS-CoV-2 감염의 새로운 슈도바이러스 기반 마우스 모델Research Published on 2021-04-302022-09-10 Journal: Journal of Biomedical Science [Category] MERS, SARS, 변종, 진단, [키워드] ACE2 addition Adenovirus administration angiotensin animal model binding can be used cause characterized co-transfection coronavirus coronavirus disease Coronavirus disease 2019 Coronaviruses COVID-19 COVID-19 pandemic demonstrated followed by Gag generate hACE2 HIV human ACE2 human Angiotensin-converting enzyme Human angiotensin-converting enzyme 2 human cell human cells infect Infection Intervention intranasal lentivirus lentiviruses luciferase-expressing mice non-infectious Outbreaks Plasmid Prevent pseudovirus purified Research respiratory Result SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 pseudovirus SARS-CoV-2 spike protein simple Spike protein Spread Strains supplementary material the SARS-CoV-2 transfection variant virulent virus worldwide pandemic [DOI] 10.1186/s12929-021-00729-3 PMC 바로가기 [Article Type] Research
Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques붉은털 원숭이의 점막 백신에 의한 SARS-CoV-2 감염에 대한 보호Research Article Published on 2021-04-282022-09-10 Journal: JCI Insight [Category] MERS, SARS, 진단, 치료기술, [키워드] Adaptive immunity binding boost cellular immunity complementary controls COVID-19 demonstrated detectable dimeric Efficacy elicited IFN-α IgA IL-15 immunization Innate immunity intramuscularly intranasal Lower respiratory tract mucosal multiple dose multiple doses naive controls nasal Nasal cavity neutralizing antibody PROTECT protection Protective protective mechanism protective mechanisms respiratory response rhesus macaque rhesus macaques RNA robust Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine Spike protein spike protein S1 Subunit vaccine subunit vaccines systemically T cell TLR agonists Vaccine Vaccines Viral viral replication virus [DOI] 10.1172/jci.insight.148494 PMC 바로가기 [Article Type] Research Article
Fluticasone Propionate Suppresses Poly(I:C)-Induced ACE2 in Primary Human Nasal Epithelial Cells플루티카손 프로피오네이트는 1차 인간 비강 상피 세포에서 폴리(I:C) 유도 ACE2를 억제합니다Cellular and Infection Microbiology Published on 2021-04-262022-09-11 Journal: Frontiers in Cellular and Infection Microbiology [Category] MERS, SARS, 치료기술, [키워드] ACE2 ACE2 expression ACE2 protein Activation Affect affected agonist analyses angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 cell entry collected Corticosteroid COVID-19 dissemination enzyme epithelial cells evaluate examined expression expression of gene fluticasone fluticasone propionate Fold change followed by Gene Expression Health health problem HNECs host cells Human immunoblot immunofluorescence incubated Incubation individuals Infection initial innate immune interferon intranasal intranasal steroid spray investigated mRNA expression nasal Nasal cavity nasal epithelial cell nasal mucosa NFκB objective poly(I:C poly(I:C) promote propionate protease Protein quantitative PCR receptor regulated required reservoir Result SARS-CoV-2 SARS-CoV-2 cell SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 viral SARS-CoV2 Serine serine 2 significantly increased Spread steroid suppresse suppressed thought TLR TLR agonists TLR3 TMPRSS2 Toll-like receptors transmembrane transmembrane protease serine 2 Viral virus infection [DOI] 10.3389/fcimb.2021.655666 PMC 바로가기 [Article Type] Cellular and Infection Microbiology